Pharma Business - November 11, 2019
Novo Nordisk obtains worldwide licence to potential NASH candidate
Novo Nordisk and UBE Industries have announced that Novo Nordisk has obtained an exclusive worldwide licence to UBE’s preclinical asset UD-014, a selective Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) inhibitor small molecule, which has shown promising efficacy in preclinical studies for its anti-inflammatory mechanism of action and antioxidative effect on endothelial cells, and can potentially […]
Agreement - October 14, 2019
Novo Nordisk and bluebird bio in research agreement
The two companies have entered into a three-year research collaboration to jointly develop in vivo genome editing treatments for genetic diseases, including haemophilia. During collaboration, bluebird and Novo Nordisk will focus on identifying a development gene therapy candidate with the ambition of offering people with haemophilia A a lifetime free of factor replacement therapy. The […]
Pharma Business - September 23, 2019
Novo Nordisk’s Rybelsus – the first GLP-1 in a tablet approved in the US
Novo Nordisk has announced that the US Food and Drug Administration (FDA) has approved Rybelsus (semaglutide tablets), as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. Rybelsus, the brand name for oral semaglutide in the US, is the first approved glucagon-like peptide-1 (GLP-1) receptor agonist in […]
Agreement - September 16, 2019
Novo Nordisk and Medtronic enter agreement
The two companies have announced a collaboration that will develop solutions to integrate insulin dosing data from future Novo Nordisk smart insulin pens into Continuous Glucose Monitoring (CGM) devices from Medtronic. This new, non-exclusive collaboration reflects both companies′ commitment to making diabetes management easier by integrating key health technologies, they state. “Millions of people living […]
Pharma Business - August 28, 2019
Novo Nordisk’s Fiasp approved in Europe for adolescents and children
The European Commission has granted an extension of the indication for Fiasp (fast-acting insulin aspart), approving it for the treatment of diabetes in adolescents and children (aged one year and above). This complements the previous indication, which covered adults only. “We are very pleased with the decision of the European Commission to expand the indication […]
Legal Advice - August 22, 2019
Securities lawsuit filed in Denmark against Novo Nordisk
Novo Nordisk A/S has been informed that a securities lawsuit has been filed against the company in Denmark. The lawsuit is filed by a number of shareholders. The claim is for a total amount of DKK 11,785,192,218 ($1.75 billion) based on their trading and holding of shares in Novo Nordisk A/S during the period 3 […]
